Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
494
datasets available to search
ShareScore release 0.9.0
Dataset results
494 results for “VEGF”
Genetic association analysis of anti-VEGF treatment response in neovascular age-related macular degeneration
<p>Summary statisics of an association study of 6,908,005 genetic variants with anti-VEGF nAMD treatment response in 179 treatment-naïve nAMD probands. This dataset supplements the publication "Genetic Association Analysis of Anti-VEGF Treatment Response in Neovascular Age-Related Macular Degeneration" (DOI: 10.3390/ijms23116094). Details regarding the methods and version numbers can be found in the corresponding manuscript.</p>
Fibrin bead assay with VEGF-A stimulation.
<p>Confocal microscopy images of fibrin bead assay. </p> <p>Related article for citation: <a href="https://www.nature.com/articles/s41598-023-33090-6">https://www.nature.com/articles/s41598-023-33090-6</a> "SproutAngio: an open-source bioimage informatics tool for quantitative analysis of sprouting angiogenesis and lumen space"</p> <p>Cells: Human umbilical vein endothelial cells (HUVECs) were isolated, maintained in PromoCell Endothelial Cell Growth Medium (Heidelberg, Germany) with 1X endothelial growth kit addition, and used in passage 2. Human lung pulmonary fibroblasts (hPFs) were purchased from PromoCell, maintained in DMEM with 10% FBS, and used in passage 8.</p> <p>Experimental groups with VEGF-A concentrations: Group1 (no VEGFA), Group2 (1 ng/ml VEGFA), Group3 (10 ng/ml VEGFA), Group4 (20 ng/ml VEGFA), Group5 (50 ng/ml VEGFA)</p> <p>We used VEGF-A from R&D Systems, Minneapolis, MN for the stimulation. Media change and VEGF-A stimulation were done on days 0,2,4,6. Assay fixation was on day 7.</p> <p>Staining: DAPI staining for nuclei, phalloidin staining for F-actin.</p>
Dataset related to: Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF-A/caveolin-1/PV-1 signaling pathway
<p>The files contain all the dataset included in the manuscript divided by figures.</p> <p>Abstract<br> In addition to having blood glucose-lowering effects, inhibitors of sodium glucose cotransporter 2 (SGLT2) afford renoprotection in diabetes. We sought to investigate which components of the glomerular filtration barrier could be involved in the antiproteinuric and renoprotective effects of SGLT2 inhibition in diabetes. BTBR (black and tan, brachyuric) <em>ob/ob</em> mice that develop a type 2 diabetic nephropathy received a standard diet with or without empagliflozin for 10 weeks, starting at 8 weeks of age, when animals had developed albuminuria. Empagliflozin caused marked decreases in blood glucose levels and albuminuria but did not correct glomerular hyperfiltration. The protective effect of empagliflozin against albuminuria was not due to a reduction in podocyte damage as empagliflozin did not affect the larger podocyte filtration slit pore size nor the defective expression of nephrin and nestin. Empagliflozin<br> did not reduce the thickening of the glomerular basement membrane. In BTBR <em>ob/ob</em> mice, the most profound abnormality seen using electron microscopy was in the endothelial aspect of the glomerular capillary, with significant loss of endothelial fenestrations. Remarkably, empagliflozin ameliorated the subverted microvascular endothelial ultrastructure. Caveolae and bridging diaphragms between adjacent endothelial fenestrae were seen in diabetic mice and associated with increased expression of caveolin-1 and the appearance of PV-1. These endothelial abnormalities were limited by the SGLT2 inhibitor. Although no expression of SGLT2 was found in glomerular endothelial cells, SGLT2 was expressed in the podocytes of diabetic mice. VEGF-A, which is a known stimulus for endothelial caveolin-1 and PV-1, was increased in podocytes of BTBR <em>ob/ob</em> mice and normalized by SGLT2 inhibitor treatment.<br> Thus, empagliflozin’s protective effect on the glomerular endothelium of diabetic mice could be due to a limitation of the paracrine signaling of podocyte-derived VEGF-A that resulted in a reduction of the abnormal endothelial caveolin-1 and PV-1, with the consequent preservation of glomerular endothelial function and permeability.</p>
Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease
ClinicalTrials.gov study NCT04419467. IPD Sharing: YES. Countries: 6. Publications: 1.
Raw Data for the article: Extracellular Vesicle-Derived microRNAs of Human Wharton's Jelly Mesenchymal Stromal Cells May Activate Endogenous VEGF-A to Promote Angiogenesis
<p>Despite low levels of vascular endothelial growth factor (VEGF)-A, the secretome of human Wharton's jelly (WJ) mesenchymal stromal cells (MSCs) effectively promoted proangiogenic responses in vitro, which were impaired upon the depletion of small (~140 nm) extracellular vesicles (EVs). The isolated EVs shared the low VEGF-A profile of the secretome and expressed five microRNAs, which were upregulated compared to fetal dermal MSC-derived EVs. These upregulated microRNAs exclusively targeted the <em>VEGF-A</em> gene within 54 Gene Ontology (GO) biological processes, 18 of which are associated with angiogenesis. Moreover, 15 microRNAs of WJ-MSC-derived EVs were highly expressed (Ct value ≤ 26) and exclusively targeted the thrombospondin 1 (<em>THBS1</em>) gene within 75 GO biological processes, 30 of which are associated with the regulation of tissue repair. The relationship between predicted microRNA target genes and WJ-MSC-derived EVs was shown by treating human umbilical-vein endothelial cells (HUVECs) with appropriate doses of EVs. The exposure of HUVECs to EVs for 72 h significantly enhanced the release of VEGF-A and THBS1 protein expression compared to untreated control cells. Finally, WJ-MSC-derived EVs stimulated in vitro tube formation along with the migration and proliferation of HUVECs. Our findings can contribute to a better understanding of the molecular mechanisms underlying the proangiogenic responses induced by human umbilical cord-derived MSCs, suggesting a key regulatory role for microRNAs delivered by EVs.</p>
Overexpression of VEGF in dermal fibroblast cells accelerates the angiogenesis and wound healing function: in vitro and in vivo studies
<p>Human dermal fibroblasts (Hu02) were transfected by pcDNA3.1(-)-VEGF vector. Following selecting fibroblast cells with hygromycin, recombinant cells were investigated in terms of VEGF expression by quantifying method. We used Real-Time PCR assay to quantitate gene expression of vascular endothelial growth factor from manipulated cells and represented VEGF overexpression.</p> <p>Reverse transcription was performed from 1 μg of total RNA transcribed to complementary DNA (cDNA) through 1 μL of random hexamer primer. The reactions were incubated at 70°C for 5 minutes. After that, 5X RT-buffer, dNTP, and RT-enzyme were added, and the mixtures were incubated at 42°C for 60 minutes and 70°C for 10 minutes. Reverse transcription was performed from 500 ng total RNA using the RT2 First Strand Kit (SA Biosciences). Quantitative real-time PCR was performed (Ampliqon, Denmark) with 40 cycles at 95 oC for 15 seconds and 60 oC for 60 seconds.</p> <p>The normalization and all the data analysis were performed according to RESR and Graph pad-Prism 8 software.<br> For the normalization, it uses the housekeeping gene: β-Actin.<br> Target gene signals normalized to housekeeping genes; 2^-deltaCt, where deltaCt = (Ct_Target − Ct_HKG)].<br> </p>
Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery
ClinicalTrials.gov study NCT07301775. IPD Sharing: YES. Countries: 1. Publications: 14.
Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy
ClinicalTrials.gov study NCT01950741. IPD Sharing: NO. Countries: 1. Publications: 5.
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer
ClinicalTrials.gov study NCT01255137. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
ClinicalTrials.gov study NCT01012973. IPD Sharing: Not stated. Countries: 10. Publications: 2.
A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab
ClinicalTrials.gov study NCT02859441. IPD Sharing: Not stated. Countries: 1. Publications: 1.
AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
ClinicalTrials.gov study NCT00396591. IPD Sharing: Not stated. Countries: 3. Publications: 1.
Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment
ClinicalTrials.gov study NCT04707625. IPD Sharing: NO. Countries: 1. Publications: 4.
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
ClinicalTrials.gov study NCT03472560. IPD Sharing: YES. Countries: 8. Publications: 1.
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
ClinicalTrials.gov study NCT00911170. IPD Sharing: Not stated. Countries: 17. Publications: 1.
Phase II Combination Steroid and Anti-VEGF for Persistent DME
ClinicalTrials.gov study NCT01945866. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
ClinicalTrials.gov study NCT00327444. IPD Sharing: Not stated. Countries: 9. Publications: 2.
A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema
ClinicalTrials.gov study NCT01918371. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement
ClinicalTrials.gov study NCT01783886. IPD Sharing: Not stated. Countries: 4. Publications: 2.
ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD)
ClinicalTrials.gov study NCT01213082. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.